In 80 patients aged ≥16 with hereditary angioedema (C1 inhibitor deficiency), one infusion of CRISPR-based lonvo-z cut monthly attacks in weeks 5–28 to 0.26 vs 2.10 with placebo (−87%). Infusion reactions, headache and fatigue were common; no serious events.
RCTn = 80
Cohn et al. Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema